128767-12-4

Basic information

• Product Name: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)
• Synonyms: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB);(±)-MBDB HCl;(+\-)-MBDB hydrochloride solution;1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine:hydrochloride
• CAS NO: 128767-12-4
• Molecular Formula: C12H18ClNO2
• Molecular Weight: 243.72982
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 128767-12-4.mol
• Article Data: 2

Chemical Properties

• Flash Point: 9℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(CAS DataBase Reference)
• NIST Chemistry Reference: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(128767-12-4)
• EPA Substance Registry System: ((±))-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine hydrochloride (MBDB)(128767-12-4)

Safety Data

• Hazard Codes: F,T
• Statements: 11-23/24/25-39/23/24/25
• Safety Statements: 16-36/37-45
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 1
• Hazardous Substances Data: 128767-12-4(Hazardous Substances Data)

Usage

Uses

MBDB ia an analog of MDMA (M303985). MBDB is the N-methylated derivative of BDB (B198900), a hallucinogenic Phenylethylamine derivative. BDB is more potent than MBDB. MBDB is a CNS stimulant.

General Description

A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research. MBDB is an illicit drug structurally related to MDMA, with similar effects including euphoria and mild stimulation.

Upstream product

• 107447-03-0 1-(3,4-methylenedioxyphenyl)-2-butanamine 
• 16929-04-7 (E)-5-(but-1-en-1-yl)benzo[d][1,3]dioxole 
• 1211-65-0 1-(3,4-Methylenedioxyphenyl)-2-nitro-1-butene 
• 120-57-0 piperonal 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 23023-13-4 1-(1,3-benzodioxol-5-yl)butan-2-one 
• 74-89-5 methylamine 
• 929532-16-1 N-(1-Benzo[1,3]dioxol-5-ylmethyl-propyl)-formamide 

Relevant articles and documents

Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines

Background and purpose: Illegal 'ecstasy' tablets frequently contain 3,4-methylenedioxymethamphetamine (MDMA)-like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [3H]noradrenaline uptake into rat PC12 cells expressing the noradrenaline transporter (NET) and [3H]5-HT uptake into HEK293 cells stably transfected with the 5-HT transporter (SERT). Experimental approach: Concentration-response curves for the following compounds at both NET and SERT were determined under saturating substrate conditions: 4-hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH), 2,5-dimethoxy-4- bromophenylethylamine (2CB), 3,4-dimethoxymethamphetamine (DMMA), 3,4-methylenedioxyphenyl-2-butanamine (BDB), 3,4-methylenedioxyphenyl-N-methyl- 2-butanamine (MBDB) and 2,3-methylenedioxymethamphetamine (2,3-MDMA). Key results: 2,3-MDMA was significantly less potent than MDMA at SERT, but equipotent with MDMA at NET. 2CB and BDB were both significantly less potent than MDMA at NET, but equipotent with MDMA at SERT. MBDB, DMMA, MDOH and the MDMA metabolites HMA and HMMA, were all significantly less potent than MDMA at both NET and SERT. Conclusions and implications: This study provides an important insight into the structural requirements of MDMA analogue affinity at both NET and SERT. It is anticipated that these results will facilitate understanding of the likely pharmacological actions of structural analogues of MDMA.